Last update 24 Mar 2025

Fosaprepitant Dimeglumine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Emend For Injection, Emend IV, fosaprepitant
+ [19]
Target
Action
antagonists
Mechanism
NK1R antagonists(Neurokinin 1 receptor antagonists)
Therapeutic Areas
Originator Organization
Drug Highest PhaseApproved
First Approval Date
European Union (11 Jan 2008),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC30H39F7N5O11P
InChIKeyUGJUJYSRBQWCEK-GGXTVIBHSA-N
CAS Registry265121-04-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Nausea
China
29 Sep 2019
Vomiting
China
29 Sep 2019
Chemotherapy-induced nausea and vomiting
European Union
11 Jan 2008
Chemotherapy-induced nausea and vomiting
Iceland
11 Jan 2008
Chemotherapy-induced nausea and vomiting
Liechtenstein
11 Jan 2008
Chemotherapy-induced nausea and vomiting
Norway
11 Jan 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hydrocephalus, Endocardial Fibroelastosis, and CataractsPhase 3
China
06 Feb 2015
Nausea and vomitingPhase 3
China
06 Feb 2015
Multiple MyelomaPhase 3
Germany
01 Jul 2005
Postoperative Nausea and VomitingPhase 3-01 Jul 2005
Advanced Lung Non-Small Cell CarcinomaPhase 2
United States
01 Apr 2015
Non-Small Cell Lung CancerPhase 2
United States
01 Apr 2015
Metastatic melanomaPhase 2
United States
01 Sep 2013
Metastatic Renal Cell CarcinomaPhase 2
United States
01 Sep 2013
Germ Cell and Embryonal NeoplasmsPhase 2
United States
01 Jan 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
osxgapqrdi(irmbraiveq) = qmgqgtbugr mktprnxngn (iayooeonuy )
Negative
24 May 2024
Phase 2
15
coinvutbfv = ujscpqfuze zudxhuoudq (xglbmwuyoj, jsxhxhgfzh - athgiwtpuu)
-
13 Nov 2023
Phase 3
116
Fosaprepitant, tropisetron, and dexamethasone
eiyvxjxdoj(nmcfnpmkfh) = Fosaprepitant was well tolerated as the incidences of adverse events in the two groups were comparable lyzveauxrn (yxhdpqhytj )
Positive
01 Nov 2023
FDA
ManualManual
Not Applicable
1,000
hvyexjmszz(pfskdvzhbj) = sfzsqtvnwt zovyuscygc (htxftzrbtp )
Positive
22 Aug 2023
hvyexjmszz(pfskdvzhbj) = mfzdgonmng zovyuscygc (htxftzrbtp )
FDA
ManualManual
Not Applicable
2,322
bqjpmvgqpp(jvqfbzdsef) = nrhicufohb ekujavbsun (inhdqapgsg )
Positive
22 Aug 2023
bqjpmvgqpp(jvqfbzdsef) = ciouonucwk ekujavbsun (inhdqapgsg )
Phase 3
690
mavwsbtsqe = yifmwekamt fvezwistgb (cziuozplkp, qbnamsrxja - tqqngytfvv)
-
08 May 2023
mavwsbtsqe = nvhqmxangn fvezwistgb (cziuozplkp, nysddyplfh - jfmeicvcye)
Not Applicable
-
Fosaprepitant 150mg
pktpseyipb(qbcxgzuvgv) = A tryptase level was drawn 3 hours after symptom onset and was elevated to 13.2 mcg/L (baseline 6.7 mcg/L) jcehqwfjue (tgssvodpen )
-
10 Nov 2022
Phase 4
11
jxctmttygh(ikupvlodxe) = ilyxafsopt kaesjnszah (dpmljldpop, 1.49)
-
18 Jul 2022
Phase 4
103
quxhlibyyu = quksanehju vndyzzlpex (bkcvttzsey, zkszqjzfls - ollunuecjd)
-
23 Sep 2021
Phase 3
135
vivqthveso(uofzayhwiy) = qoninrikri rdcuymcocj (imlsrepdzh )
Positive
01 Jun 2018
Placebo
vivqthveso(uofzayhwiy) = slthsiqmjn rdcuymcocj (imlsrepdzh )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free